AR077915A1 - Forma cristalina de pemirolast - Google Patents

Forma cristalina de pemirolast

Info

Publication number
AR077915A1
AR077915A1 ARP100102136A ARP100102136A AR077915A1 AR 077915 A1 AR077915 A1 AR 077915A1 AR P100102136 A ARP100102136 A AR P100102136A AR P100102136 A ARP100102136 A AR P100102136A AR 077915 A1 AR077915 A1 AR 077915A1
Authority
AR
Argentina
Prior art keywords
pemirolast
crystal form
sodium salt
hemihydrated
hemihydrated form
Prior art date
Application number
ARP100102136A
Other languages
English (en)
Spanish (es)
Inventor
Ulrika Rosenstrom
Karol Horvath
Anett Perlberg
Martin Viertelhaus
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of AR077915A1 publication Critical patent/AR077915A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Secondary Cells (AREA)
  • Dental Preparations (AREA)
ARP100102136A 2009-06-16 2010-06-16 Forma cristalina de pemirolast AR077915A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18734809P 2009-06-16 2009-06-16
US18735509P 2009-06-16 2009-06-16

Publications (1)

Publication Number Publication Date
AR077915A1 true AR077915A1 (es) 2011-10-05

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102136A AR077915A1 (es) 2009-06-16 2010-06-16 Forma cristalina de pemirolast

Country Status (31)

Country Link
US (3) US20120157415A1 (OSRAM)
EP (2) EP3141549A1 (OSRAM)
JP (2) JP5722317B2 (OSRAM)
KR (2) KR20170049645A (OSRAM)
CN (1) CN102596202B (OSRAM)
AR (1) AR077915A1 (OSRAM)
AU (1) AU2010261540B2 (OSRAM)
BR (1) BRPI1015559A2 (OSRAM)
CA (1) CA2765408A1 (OSRAM)
CY (1) CY1118413T1 (OSRAM)
DK (1) DK2443120T3 (OSRAM)
EA (1) EA025865B1 (OSRAM)
ES (1) ES2613059T3 (OSRAM)
HR (1) HRP20170023T1 (OSRAM)
HU (1) HUE032978T2 (OSRAM)
IL (1) IL216670A (OSRAM)
LT (1) LT2443120T (OSRAM)
ME (1) ME02685B (OSRAM)
MX (1) MX2011013676A (OSRAM)
NZ (1) NZ596747A (OSRAM)
PL (1) PL2443120T3 (OSRAM)
PT (1) PT2443120T (OSRAM)
RS (1) RS55558B1 (OSRAM)
SA (1) SA114350792B1 (OSRAM)
SG (1) SG176295A1 (OSRAM)
SI (1) SI2443120T1 (OSRAM)
SM (2) SMT201700085T1 (OSRAM)
TW (1) TWI504599B (OSRAM)
UY (1) UY32711A (OSRAM)
WO (2) WO2010146348A2 (OSRAM)
ZA (1) ZA201109045B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510837A (ja) * 2009-11-13 2013-03-28 カルドズ・アーベー 全身性軽度炎症の新しい処置
AU2013381855B2 (en) * 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
JP6596697B2 (ja) * 2016-10-03 2019-10-30 ブリベンションファーマシューティカル(シャンハイ)インコーポレイテッド Trhアナログ及びアルンド酸を組み合わせてなる組成物、並びにアルンド酸の薬学的に許容される塩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド[1,2―a]ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
US8686189B2 (en) 2005-09-16 2014-04-01 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
ES2394984T3 (es) 2006-12-18 2013-02-07 Cardoz Ab Nueva combinación para uso en el tratamiento de trastornos inflamatorios
AU2007336077A1 (en) 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
JP2012530118A (ja) 2012-11-29
BRPI1015559A2 (pt) 2016-04-26
EA201200017A1 (ru) 2013-10-30
US20120157415A1 (en) 2012-06-21
MX2011013676A (es) 2012-02-08
US20140329839A1 (en) 2014-11-06
AU2010261540B2 (en) 2016-04-14
CY1118413T1 (el) 2017-06-28
CA2765408A1 (en) 2010-12-23
TWI504599B (zh) 2015-10-21
SMT201700085B (it) 2017-03-08
WO2010146348A2 (en) 2010-12-23
IL216670A0 (en) 2012-02-29
JP5722317B2 (ja) 2015-05-20
PL2443120T3 (pl) 2017-04-28
WO2010146341A3 (en) 2011-03-03
ME02685B (me) 2017-06-20
WO2010146348A9 (en) 2012-05-03
CN102596202A (zh) 2012-07-18
WO2010146348A3 (en) 2011-03-03
WO2010146341A2 (en) 2010-12-23
HRP20170023T1 (hr) 2017-03-10
SMT201700085T1 (it) 2017-03-08
ZA201109045B (en) 2013-05-29
EP3141549A1 (en) 2017-03-15
KR20120032530A (ko) 2012-04-05
IL216670A (en) 2017-02-28
AU2010261540A2 (en) 2012-01-19
UY32711A (es) 2011-01-31
LT2443120T (lt) 2017-02-10
ES2613059T3 (es) 2017-05-22
DK2443120T3 (en) 2017-01-09
US20170202839A1 (en) 2017-07-20
HUE032978T2 (hu) 2017-11-28
EA025865B1 (ru) 2017-02-28
SG176295A1 (en) 2012-01-30
PT2443120T (pt) 2017-02-08
SI2443120T1 (sl) 2017-04-26
SA114350792B1 (ar) 2015-11-10
CN102596202B (zh) 2015-01-21
NZ596747A (en) 2014-01-31
TW201100422A (en) 2011-01-01
KR20170049645A (ko) 2017-05-10
US9006431B2 (en) 2015-04-14
EP2443120B1 (en) 2016-11-02
EP2443120A2 (en) 2012-04-25
AU2010261540A1 (en) 2012-01-19
JP2015120750A (ja) 2015-07-02
RS55558B1 (sr) 2017-05-31

Similar Documents

Publication Publication Date Title
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
EA201270254A1 (ru) Производные 5-фторпиримидинона
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
MA32369B1 (fr) Composes de benzene sulfonamide thiazole et oxazole
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
BR112013033568A2 (pt) compostos éter amidopiridil e composições e seu uso contra parasitas
DK2193795T3 (da) Latanoprostholdig vandig farmaceutisk sammensætning
BRPI1014821A2 (pt) "inibidores de replicação de hiv"
EA201101097A1 (ru) Новые микробиоциды
EP2305237A4 (en) THERAPEUTIC AGENT FOR MALE STERILITY
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
UY32711A (es) Nueva forma cristalina de pemirolast
BRPI1013037A2 (pt) "solução farmacêutica oral de telmisartan"
FR2957225B1 (fr) Procede d'elevage de coquillages, notamment des huitres.
EP2318512A4 (en) INSULATION OF NEW BACTERIA FOR THE SUPPRESSION OF SOILY DISEASES
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом

Legal Events

Date Code Title Description
FB Suspension of granting procedure